Mashup Score: 4
Urology Times“This represents one of the largest reported in the phase 3 trials in first-line mCRPC,” says investigator Noel W. Clarke, MBBS, FRCS, ChM.
See more from Catherine Marshall
I disagree with the headline but looks like this is the link that is postable. Final overall survival data for PROpel – (abi + olaparib in first line mCRPC). Not fully mature, trend towards improvement, greatest in patients with BRCA mutated disease with almost no difference in the patients with non BRCA mutated disease.